Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $4.49 billion. The enterprise value is $3.50 billion.
Important Dates
The last earnings date was Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 82.32 million shares outstanding. The number of shares has increased by 23.38% in one year.
| Current Share Class | 82.32M |
| Shares Outstanding | 82.32M |
| Shares Change (YoY) | +23.38% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 1.40% |
| Owned by Institutions (%) | 98.83% |
| Float | 69.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.57 |
| P/TBV Ratio | 4.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.83, with a Debt / Equity ratio of 0.00.
| Current Ratio | 15.83 |
| Quick Ratio | 15.48 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -71.46 |
Financial Efficiency
Return on equity (ROE) is -34.53% and return on invested capital (ROIC) is -23.81%.
| Return on Equity (ROE) | -34.53% |
| Return on Assets (ROA) | -22.63% |
| Return on Invested Capital (ROIC) | -23.81% |
| Return on Capital Employed (ROCE) | -34.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.65M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.42% in the last 52 weeks. The beta is -0.40, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.40 |
| 52-Week Price Change | +76.42% |
| 50-Day Moving Average | 52.78 |
| 200-Day Moving Average | 48.15 |
| Relative Strength Index (RSI) | 67.40 |
| Average Volume (20 Days) | 1,711,135 |
Short Selling Information
The latest short interest is 4.32 million, so 5.25% of the outstanding shares have been sold short.
| Short Interest | 4.32M |
| Short Previous Month | 4.41M |
| Short % of Shares Out | 5.25% |
| Short % of Float | 6.18% |
| Short Ratio (days to cover) | 2.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -330.02M |
| Pretax Income | -292.82M |
| Net Income | -292.82M |
| EBITDA | -329.99M |
| EBIT | -330.02M |
| Earnings Per Share (EPS) | -$3.74 |
Full Income StatementBalance Sheet
The company has $737.83 million in cash and $605,000 in debt, giving a net cash position of $987.71 million or $12.00 per share.
| Cash & Cash Equivalents | 737.83M |
| Total Debt | 605,000 |
| Net Cash | 987.71M |
| Net Cash Per Share | $12.00 |
| Equity (Book Value) | 957.64M |
| Book Value Per Share | 11.95 |
| Working Capital | 706.88M |
Full Balance SheetCash Flow
| Operating Cash Flow | -250.17M |
| Capital Expenditures | n/a |
| Free Cash Flow | -250.17M |
| FCF Per Share | -$3.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |